David H. Ilson
Memorial Sloan Kettering Cancer Center · 923 works · 20,732 citations · h-index 66
Top works
- Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
- Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
- Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial
- Esophageal and Esophagogastric Junction Cancers, Version 1.2015
- Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer
- Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer
- Gastric Cancer, Version 2.2013
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
- A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors.
- Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer